Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Gains from Sales and Divestitures (2023 - 2025)

Core Laboratories (CLB) has 2 years of Gains from Sales and Divestitures data on record, last reported at $256724.0 in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures fell 23.79% year-over-year to $256724.0; the TTM value through Dec 2024 reached $256724.0, down 23.79%, while the annual FY2024 figure was $256724.0, 23.79% down from the prior year.
  • Gains from Sales and Divestitures reached $256724.0 in Q4 2024 per CLB's latest filing, down from $336844.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $336844.0 in Q4 2023 and bottomed at $256724.0 in Q4 2024.